Phase 2 Start~month

Phase 2 Start: A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer

Indication
Small Cell Lung Cancer ( SCLC )

Other upcoming events for PBYI

Patent ExpiryPatent/Exclusivity Expiry: NERLYNX

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Start: A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer — PBYI Phase 2 Start | BioSniper